Table 1 Baseline characteristics of the 150 patients treated with or without prednisolone
Prednisolone n = 70 | No prednisolone n = 80 | p level | |
|---|---|---|---|
Age, years | 51.3(48.2 to 54.4) | 58.4 (55.6 to 61.2) | 0.001 |
Disease duration, months | 6.3 (5.5 to 7.1) | 5.7 (5.1 to 6.4) | 0.27 |
Women, % | 69 | 65 | 0.64 |
Menopause, % | 50 | 69 | 0.05 |
Menopause age, years* | 50(48 to 51) | 50(47 to 52) | 0.97 |
Current or previous smoker, % | 67 | 56 | 0.13 |
BMI*, kg/m2 | 24.3 (22.5 to 27.0) | 25.6 (23.5 to 29.1) | 0.07 |
RF positivity, % | 66 | 55 | 0.25 |
Erosive disease, % | 53 | 56 | 0.68 |
DAS28 | 5.2 (4.9 to 5.5) | 5.5 (5.3 to 5.7) | 0.12 |
ESR | 39(33 to 44) | 39(33 to 45) | 0.96 |
CRP* | 22(10 to 45) | 21(10 to 58) | 0.50 |
IL-6* | 9.9(8.0 to 19.4) | 11.7(9.2 to 27.6) | 0.44 |
HAQ | 1.0 (0.9 to 1.2) | 1.0 (0.8 to 1.1) | 0.52 |
Z-score, L2–L4* | 0.36 (-0.24 to 0.88) | 0.50 (-0.36 to 1.37) | 0.29 |
Z-score neck* | 0.01 (-0.56 to 1.00) | -0.02 (-0.52 to 0.69) | 0.87 |
P1NP*, μg/L | 38.3 (28.0 to 51.8) | 40.8 (28.8 to 57.0) | 0.50 |
CTX-1*, ng/mL | 0.26 (0.20 to 0.35) | 0.33 (0.19 to 0.42) | 0.17 |
1CTP* μg/L | 4.5 (3.5 to 5.7) | 4.2 (3.4 to 6.4) | 0.62 |
IGF-1, μg/L* | 173 (135 to 202) | 210 (185 to 250) | 0.34 |
IGFSD | 0.15 (-0.06 to 0.6) | 1.0 (0.4 to 1.6) | 0.42 |